22 May 2013 - 22 May 2013 - US biotech group Ceregene Inc unveiled yesterday additional secondary analysis data from a Phase IIb trial of its gene therapy CERE-120 (AAV-neurturin) for Parkinson's disease.

The exploratory analysis of the double-blind, randomised, controlled trial demonstrated a stronger response to CERE-120 in Parkinson's patients diagnosed within five years before treatment, compared with patients diagnosed 10 years or more (p